Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Related Articles by Review for PubMed (Select 16947080)

1.

Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.

Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R.

Neurochem Res. 2006 Sep;31(9):1153-62. Epub 2006 Sep 1. Erratum in: Neurochem Res. 2007 Nov;32(11):2002.

PMID:
16947080
2.

Alpha-synuclein, Abeta and Alzheimer's disease.

Wirths O, Bayer TA.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):103-8. Review.

PMID:
12551731
3.

Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.

Hashimoto M, Rockenstein E, Crews L, Masliah E.

Neuromolecular Med. 2003;4(1-2):21-36. Review.

PMID:
14528050
4.

A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.

Jellinger KA.

Biochim Biophys Acta. 2009 Jul;1792(7):730-40. doi: 10.1016/j.bbadis.2008.07.006. Epub 2008 Aug 5. Review.

5.

[Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].

Orimo S.

Rinsho Shinkeigaku. 2008 Jan;48(1):11-24. Review. Japanese.

PMID:
18386627
6.

Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.

Francis PT.

J Neurol. 2009 Aug;256 Suppl 3:280-5. doi: 10.1007/s00415-009-5247-7. Review.

PMID:
19711117
7.

Lewy body pathology in Alzheimer's disease.

Kotzbauer PT, Trojanowsk JQ, Lee VM.

J Mol Neurosci. 2001 Oct;17(2):225-32. Review.

PMID:
11816795
8.

Formation and development of Lewy pathology: a critical update.

Jellinger KA.

J Neurol. 2009 Aug;256 Suppl 3:270-9. doi: 10.1007/s00415-009-5243-y. Review.

PMID:
19711116
9.

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. Review.

PMID:
19711118
10.

Neuropathology of synuclein aggregates.

Duda JE, Lee VM, Trojanowski JQ.

J Neurosci Res. 2000 Jul 15;61(2):121-7. Review.

PMID:
10878583
11.

Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.

Krüger R, Müller T, Riess O.

J Neural Transm. 2000;107(1):31-40. Review.

PMID:
10809401
12.

Interactions of amyloidogenic proteins.

Giasson BI, Lee VM, Trojanowski JQ.

Neuromolecular Med. 2003;4(1-2):49-58. Review.

PMID:
14528052
13.

Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.

Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H.

Neuropharmacology. 2003 Jul;45(1):14-44. Review.

PMID:
12814657
14.
15.

Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.

Iwai A.

Biochim Biophys Acta. 2000 Jul 26;1502(1):95-109. Review.

16.
17.

Alpha-synuclein in Lewy body disease and Alzheimer's disease.

Hashimoto M, Masliah E.

Brain Pathol. 1999 Oct;9(4):707-20. Review.

PMID:
10517509
18.
19.

Significance of brain lesions in Parkinson disease dementia and Lewy body dementia.

Jellinger KA.

Front Neurol Neurosci. 2009;24:114-25. doi: 10.1159/000197890. Epub 2009 Jan 26. Review.

PMID:
19182469
20.

Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity.

Aarsland D, Londos E, Ballard C.

Int Psychogeriatr. 2009 Apr;21(2):216-9. doi: 10.1017/S1041610208008612. Epub 2009 Jan 28. Review. No abstract available.

PMID:
19173762
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk